Join to View Full Profile
39901 Traditions DrNorthville, MI 48168
Phone+1 248-305-4400
Fax+1 248-305-4401
Dr. Akin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1996 - 1999
University of Louisville School of MedicineResidency, Internal Medicine, 1993 - 1996
Istanbul University FomClass of 1988
Certifications & Licensure
MI State Medical License 2003 - 2027
MA State Medical License 2009 - 2017
MD State Medical License 1996 - 2004
American Board of Allergy and Immunology Allergy & Immunology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2016
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2016
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2016
Clinical Trials
- Molecular Mechanisms and Diagnosis of Mastocytosis
- Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis Start of enrollment: 2011 Mar 01
Publications & Presentations
PubMed
- Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis.Thanai Pongdee, Mariana Castells, Cem Akin, Ingunn Dybedal, Jason Gotlib
The World Allergy Organization Journal. 2026-04-01 - Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.Peter Valent, Karin Hartmann, Gabriele Stefanzl, Yüksel Filik, Karin Bauer
Current Allergy and Asthma Reports. 2026-02-17 - Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.Frank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, Tracy I George, Cristina Bulai Livideanu
Journal of the American Academy of Dermatology. 2026-02-12
Lectures
- Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inade...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Other
- Original Article the Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Patient Clinical Experiences and BeyondCem Akin, MD, ScienceDirect
https://www.doximity.com/articles/b432751a-ab97-4bd1-babc-759b194081d6
UpToDate, Wolters Kluwer Health - 2013-02-08 - Original Article the Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Patient Clinical Experiences and BeyondCem Akin, MD, ScienceDirect
https://www.doximity.com/articles/b432751a-ab97-4bd1-babc-759b194081d6
UpToDate, Wolters Kluwer Health - 2012-05-11 - Original Article the Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Patient Clinical Experiences and BeyondCem Akin, MD, ScienceDirect
https://www.doximity.com/articles/b432751a-ab97-4bd1-babc-759b194081d6
UpToDate, Wolters Kluwer Health - 2012-11-19
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
